Orchestra BioMed Holdings Overview
Latest ROE for Orchestra BioMed Holdings: -201.51% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-201.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Orchestra BioMed Holdings (OBIO) currently reports a ROE of -201.51%. That is below the sector sector average of 11.73%. Use the charts on this page to explore Orchestra BioMed Holdings's ROE history and peer comparisons.
Orchestra BioMed Holdings's ROE of -201.51% is lower than the its sector sector average of 11.73%. That is roughly 1817.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Orchestra BioMed Holdings's current -201.51% should be judged against industry norms (sector average: 11.73%) and against OBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -201.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.73%. From there, open related valuation or income-statement pages for Orchestra BioMed Holdings, and consider following OBIO for alerts when major investors trade the stock.
